{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:22:46Z","timestamp":1787638966212,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Belimumab has emerged as a therapeutic option for lupus nephritis (LN); however, real-world evidence on its effectiveness remains limited. This study aimed to evaluate the effectiveness and safety of belimumab and to identify renal and immunological predictors of response in Spanish patients with LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, multicenter study including patients with biopsy-confirmed LN treated with belimumab between 2012 and 2024. Outcomes included primary efficacy renal response (PERR), complete renal response (CRR), changes in proteinuria, estimated glomerular filtration rate (eGFR), urinary sediment, histological parameters, and immunological serologic markers, including anti\u2013double-stranded DNA antibodies (anti-dsDNA), complement components C3 and C4, and erythrocyte sedimentation rate(ESR). Renal flares were defined according to the BLISS-LN criteria. Data on disease activity (SLEDAI-2K), adverse events, and concomitant immunosuppressive therapies were also collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 202 patients, predominantly women (87.5%), with mainly proliferative LN (79.7%). At 6, 12, and 24 months, PERR was achieved in 70.7%, 71.1%, and 72.7% of patients, respectively, while CRR rates were 52.4%, 47.6%, and 49.1%. These outcomes were consistent with those reported in the BLISS-LN and BeRLiSS-LN trials. Early initiation of belimumab was associated with greater improvement in renal and immunological serologic markers. A \u226550% reduction in anti-dsDNA levels at 12 months was associated with higher odds of achieving PERR (OR 3.91, 95%CI 1.00\u201315.30;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.050). In a small subgroup undergoing repeat biopsy, histological activity index improved after treatment initiation. SLEDAI-2K score significantly decreased (p&amp;lt;0.001), accompanied by a low rate of renal flares. Prednisone and mycophenolate mofetil (MMF) doses decreased significantly during follow-up. Belimumab was well tolerated, with few discontinuations due to adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Belimumab use was associated with maintenance or improvement of renal response in a real-world cohort of patients with LN. The apparent benefits of early initiation, together with the observed reductions in corticosteroid and MMF doses, the favorable safety profile, and the low rate of renal flares, suggest that belimumab may be an effective option both in early disease and for long-term management. Furthermore, a \u226550% reduction in anti-dsDNA antibody titers may represent a useful prognostic biomarker of renal response in patients with predominantly proliferative LN treated with belimumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1897450","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:36:09Z","timestamp":1787636169000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world experience with belimumab in lupus nephritis: insights from the Spanish cohort"],"prefix":"10.3389","volume":"17","author":[{"given":"Ana","family":"Huerta","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hospital Puerta de Hierro Majadahonda","place":["Madrid, Spain"]},{"name":"Instituto Investigaci\u00f3n Puerta de Hierro-Segovia Arana, IDIPHISA","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"L\u00f3pez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Puerta de Hierro Majadahonda","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Puerta de Hierro Majadahonda","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Quintana","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Clinic, Universidad de Barcelona, Instituto de Investigaciones Biom\u00e9dicas August Pi i Sunyer (IDIBAPS)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adoraci\u00f3n","family":"Mart\u00edn-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Poniente","place":["Almer\u00eda, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Ramon y Cajal","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rabasco","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Reina Sofia","place":["Cordoba, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alberto","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario de Badajoz","place":["Badajoz, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario de Salamanca","place":["Salamanca, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Temprado","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Virgen del Rocio","place":["Sevilla, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Lopez-Mendoza","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Virgen del Rocio","place":["Sevilla, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jose","family":"Borrego","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario de Jaen","place":["Jaen, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Afonso","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Insular de Gran Canaria","place":["Gran Canaria, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antolina","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Clinico San Carlos","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario de Navarra","place":["Navarra, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gago","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Central de Asturias","place":["Asturias, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Carmen","family":"Prados","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Torrecardenas","place":["Almer\u00eda, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Gracia","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Miguel Servet","place":["Zaragoza, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Sierra","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario San Pedro","place":["La Rioja, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"S\u00e1nchez-Agesta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Puerto Real","place":["Cadiz, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Carbayo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Gregorio Mara\u00f1on","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Hadad","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Clinico Universitario Virgen de la Arrixaca","place":["Murcia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Romera","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital General Universitario de Ciudad Real","place":["Ciudad Real, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cox","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital General Universitario de Ciudad Real","place":["Ciudad Real, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Mora","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cl\u00ednica Universitaria de Navarra","place":["Navarra, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Rivas","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario La Paz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fernandez-Solis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital del Mar","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gomez-Preciado","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario de Bellvitge","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Mora","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Juan Ramon Jimenez","place":["Huelva, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Marquez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital del Mar","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Espino","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Hospital Universitario 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Larramendi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Hospital Universitario Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Lopez-Corbeto","sequence":"additional","affiliation":[{"name":"Unit of Pediatric Rheumatology, Hospital Universitario Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Devolder-Nicolau","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Hospital de Sant Pau","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Puente-Garcia","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Hospital Universitario de Fuenlabrada","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Shabaka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario La Paz","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital General de Segovia","place":["Segovia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mon","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Severo Ochoa","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Tato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Fundacion Alcorcon","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Villa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cl\u00ednica Universitaria de Navarra","place":["Navarra, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Galindo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital Universitario 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Martin-Testillano","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Puerta de Hierro Majadahonda","place":["Madrid, Spain"]},{"name":"Instituto Investigaci\u00f3n Puerta de Hierro-Segovia Arana, IDIPHISA","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Portol\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Puerta de Hierro Majadahonda","place":["Madrid, Spain"]},{"name":"Instituto Investigaci\u00f3n Puerta de Hierro-Segovia Arana, IDIPHISA","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/cjn.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.290","article-title":"Benlysta: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus","volume":"91","author":"Dennis","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad167","article-title":"Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial","volume":"38","author":"Anders","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of glomerular diseases","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102729","article-title":"Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN)","volume":"124","author":"Gatto","year":"2021","journal-title":"J Autoimmun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead707","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study","volume":"64","author":"Lin","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf103","article-title":"Efficacy and safety of belimumab in refractory and newly diagnosed active lupus nephritis patients: a real-world observational study","volume":"18","author":"Ma","year":"2025","journal-title":"Clin Kidney J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000529675","article-title":"Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China","volume":"9","author":"Tan","year":"2023","journal-title":"Kidney Dis. (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae495","article-title":"Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry","volume":"64","author":"Sakai","year":"2025","journal-title":"Rheumatol. (Oxford)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with Avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B26","unstructured":"Benlysta (Belimumab): Summary of Product Characteristics (Smpc)\n          \n          \n          \n          2026"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000932","article-title":"Remission of lupus nephritis: the trajectory of histological response in successfully treated patients","volume":"10","author":"Malvar","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae495","article-title":"Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry","volume":"64","author":"Sakai","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00085","article-title":"Double negative B cell is associated with renal impairment in systemic lupus erythematosus and acts as a marker for nephritis remission","volume":"7","author":"You","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00243-2","article-title":"Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the OBSErve studies","volume":"7","author":"Collins","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/rheumatology\/kead231","article-title":"SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus\u2014an analysis of anti-double-stranded DNA monitoring","volume":"63","author":"Yeo","year":"2024","journal-title":"Rheumatol. (Oxford)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.42941","article-title":"Association of autoantibody concentrations and trajectories with lupus nephritis histologic features and treatment response","volume":"76","author":"Fava","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1681\/asn.20223311s1185a","article-title":"Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with mycophenolate associated with belimumab or mycophenolate plus standard of care therapy","volume":"32","author":"Malvar","year":"2023","journal-title":"Lupus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1897450\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:36:10Z","timestamp":1787636170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1897450\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1897450"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1897450","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1897450"}}